Celgene
Top Ten most popular articles on Pharmafile.com this week
November 18, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Crohn's, Janssen, otezla, top ten
While the world is still reeling from the US presidential election results; it’s business as usual for the pharma industry; …
Celgene’s Otezla hits primary endpoint in psoriatic arthritis study
November 15, 2016Manufacturing and Production, Research and Development Celgene, otezla, psoriatic arthritis
Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment …
Celgene partners with IBM for new pharmacovigilance platform
November 2, 2016Research and Development, Sales and Marketing Celgene, Watson, ibm
IBM is set to join forces with Celgene to develop a new drug safety evaluation platform, it has emerged. Running …
Celgene’s Otezla approved by NICE for chronic plaque psoriasis
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, NICE, apremilast, otezla
NICE has given its approval to another indication for Celgene’s Otezla (apremilast), meaning NHS patients now have access to the …
Celgene trial displays promising results for Crohn’s disease alternative treatment
October 17, 2016Sales and Marketing Celgene, Celgene corporation, Crohn’s disease, clinical trials, crohn's disease, phase I, trial
Celgene International, part of Celgene Corporation, has released the results from a Phase Ib trial showing improvement in patients suffering …
NICE backs Celgene’s Otezla for psoriatic arthritis
October 12, 2016Research and Development, Sales and Marketing Celgene, NICE, otezla
The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic …
$600m acquisition bolsters Celgene’s blood cancer portfolio
October 3, 2016Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma
Celgene has shelled out $600m for Swiss biotech EngMab in an effort to reinforce its blood cancer portfolio with a …
Top ten stories in the pharmaceutical industry this week
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis
It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …
Celgene and Agios to file FDA application for “first-in-class” cancer drug
September 8, 2016Research and Development, Sales and Marketing Celgene, FDA, NDA, acute myeloid leukaemia, agios
According to an SEC 8-K filing by Agios, the company and its partner Celgene intend to file a new drug …
Celgene’s Otezla approved for NHS use
August 3, 2016Research and Development, Sales and Marketing Celgene, NHS, NICE, apremilast
NICE has published draft guidance recommending the use of Celgene’s Otezla (apremilast) for use on the NHS for treatment of …
Celgene’s Revlimid fails to improve overall survival from lymphoma in Phase III trial
July 26, 2016Research and Development Celgene, Revlimid, lymphoma
Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma …
Celgene boosts cancer portfolio with deal worth up to $2.5 billion with Jounce Therapeutics
July 19, 2016Research and Development, Sales and Marketing Celgene, jounce
Celgene has entered into a collaboration with Jounce Therapeutics that will see the pair jointly develop and commercialise Jounce’s lead …
Celgene says its Revlimid gets European approval to treat rare non-Hodgkin’s lymphoma
July 15, 2016Medical Communications, Research and Development, Sales and Marketing Celgene, European Commission, Revlimid, drug approval, drug trial, oncology
Celgene (Nasdaq: CELG) said the European Commission (EC) has approved Revlimid (lenalidomide) to treat a rare form of non-Hodgkin’s lymphoma.
AstraZeneca mulling a $10-billion bid for Medivation – report
July 12, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisition
Anglo Swedish drug firm AstraZeneca (LSE: AZN) is considering a $10-billion takeover bid for Medivation (Nasdaq: MDVN), according to reports. …
Nice rejects Celgene’s drug to treat blood cancer
June 24, 2016Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer
The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …
Latest content
FibroFind appoints Lee Borthwick as CEO
